about
Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failureMicrobial translocation in chronic liver diseasesBranched-chain amino acids for people with hepatic encephalopathyBranched-chain amino acids for people with hepatic encephalopathyProbiotics for patients with hepatic encephalopathyProbiotics for hepatic encephalopathyUsefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patientsManagement of overt hepatic encephalopathyAntibiotics for the treatment of hepatic encephalopathyEvaluation of the impact of rehospitalization in the management of hepatic encephalopathyManagement of Hepatic Encephalopathy: A PrimerRifaximin for the treatment of hepatic encephalopathyTherapy for alcoholic liver diseaseHepatic encephalopathy.Encephalopathy and liver transplantation.Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice dataNon-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.Recommendation of Repeated Ammonia Tests for Intrahepatic Portal-Systemic Shunt Without Cirrhosis in Elderly Patients With Psychiatric Symptoms.Cirrhosis and its complications: evidence based treatment.Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient.Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.Management of hepatic encephalopathy in the hospitalClinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patientsImpaired small-world network efficiency and dynamic functional distribution in patients with cirrhosis.Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome.Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.Current trends in the treatment of hepatic encephalopathy.The mind and liver test: a new approach to the diagnosis of minimal hepatic encephalopathy in resource-poor settings.Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study.Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living-donor liver transplantation.Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascitesImpact of physician specialty on quality care for patients hospitalized with decompensated cirrhosis.Advances in critical care hepatology.A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy.Postoperative resource utilization and survival among liver transplant recipients with Model for End-stage Liver Disease score ≥ 40: A retrospective cohort study.Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascitesPersistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy.Hepatobiliary Quiz (Answers)-14 (2015).
P2860
Q21195009-13BB70C4-3AEF-42CF-B051-0E116035FDC9Q21284997-00DED7DC-C01C-42D0-9BA1-CF6E647FD9D5Q24187134-AB54C041-FEB9-4574-859A-14AE31B20CA3Q24187960-40A8CD5D-5315-4338-872A-69F48CD60C06Q24235259-634B5F88-A671-4FBE-9BF0-45697412C394Q24236083-1E203C9D-51B1-49EE-9289-3B00537BED9EQ24658600-B2CC2B3C-D7D8-4F8E-9664-772F3079F04BQ26830789-817C49AA-3369-4D68-B8E6-3D3ABBD49A73Q27012878-E324EFBF-EB88-4F68-9588-C42692FDF141Q28085014-C1CB0F7D-896D-4122-85C1-F9EA62768F7AQ28275197-A2DEDAC8-0B1E-403A-BD63-838D38A85A1BQ28288610-A8D9FFEB-B0BB-4094-87AD-C57A5D25C533Q28658193-3B8D7F6D-E4C6-4639-A438-AB4C5948EA38Q30423851-29FEB6E6-D50A-4E0F-877F-8DFF54C13A5EQ30577611-8014832D-EC94-4A47-8E96-505EECFD1F56Q30807184-7749B3FD-1C91-4476-ACEF-3050F0F19BFCQ33200604-6A21BB34-E2B6-4850-8D2A-DC018D7FB723Q33583734-A246314C-B625-4565-AF29-A0F7A9531788Q33594931-F6EE1774-993D-4D17-84F0-6EC69F29AC4FQ33599299-C3752D0A-DC5A-4068-8D9E-237240D0E338Q33628162-06066937-503F-4B91-9451-E05DF2537233Q34028149-A05CDE53-527C-4A23-B412-E75AAF1E256BQ34093932-007DAE04-7BDE-4D38-95E7-C6E3288AE56AQ34259975-E59BFD9E-762D-4746-9B72-BFBFEB3BB440Q34405186-1FFEFC69-6F8F-4810-8EC2-CC12B357927DQ34509599-91A31913-EEF8-4FA6-A799-945DAF0721E2Q34530153-47DD5D88-7021-47C6-8DD0-D21AFCE44673Q34611198-4288F12F-F51D-4B95-AE2A-B76E7619749EQ34762001-B927349E-F628-4EDA-AC71-0C3D33316CE3Q34787750-584E09BD-2489-45C0-BC0F-C28DEDCF2A77Q34984112-54B644EA-E4F0-4E55-9B16-297751AA4E72Q34996031-BC4DE4E7-35A1-42B0-9AF8-F65B3466C75AQ35143004-2EE298DB-418C-4A59-BFFC-BD725D0450CBQ35250184-F977A60B-086F-4B66-94AC-1E5578C97983Q35605215-D90986EB-D589-49B1-A814-2C4EACA75D98Q35618240-E5231A87-1B18-4362-B4CD-E4AF716563BBQ35647592-8F81A6B6-D98E-4700-8234-DD05D0AAA521Q35720298-E1CB6BF8-89C0-47AD-86C8-D03BD25844D1Q35796445-87AEA0D7-BEB2-490A-BD3C-57AA6D9BC132Q35818316-374C0BD8-6BE9-46B6-9FBD-59432F0EE9A7
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Hepatic Encephalopathy.
@en
Hepatic Encephalopathy.
@nl
type
label
Hepatic Encephalopathy.
@en
Hepatic Encephalopathy.
@nl
prefLabel
Hepatic Encephalopathy.
@en
Hepatic Encephalopathy.
@nl
P2093
P1476
Hepatic Encephalopathy.
@en
P2093
Practice Parameters Committee of the American College of Gastroenterology
P304
P356
10.1111/J.1572-0241.2001.03964.X
P407
P577
2001-07-01T00:00:00Z